B. Feagan

发表

An evaluation of utility measurement in Gastro-esophageal reflux disease (GERD)

J. Gregor, A. Ethiopia, H. Preiksaitis, 1998 .

The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial

N. Rodger, J. Mahon, N. Muirhead, 1999 .

Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 study

T. Humphries, B. Feagan, J. Valentine, 2009, Gut.

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

G. Radford-Smith, R. Enns, W. Sandborn, 2004, Gut.

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

M. Silverberg, A. Bitton, G. Greenberg, 2013, Alimentary pharmacology & therapeutics.

OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial.

S. Vermeire, B. Sands, G. D'Haens, 2017, Journal of Crohn's & colitis.

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

S. Targan, G. Van Assche, J. Valentine, 2006, Gut.

OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study

J. Panés, J. Johanns, M. Germinaro, 2022, Journal of Crohn's and Colitis.

OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial

M. Silverberg, P. Gionchetti, S. Danese, 2022, Journal of Crohn's and Colitis.

OC-043 Long term efficacy and safety of ustekinumab for crohn’s disease: results from im-uniti long-term extension through 2 years

S. Targan, P. Rutgeerts, S. Hanauer, 2017, Gut.

The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12.

J. Panés, B. Bressler, J. Johanns, 2022, Gastroenterology & hepatology.

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

S. Vermeire, I. Lawrance, G. D'Haens, 2015, Alimentary pharmacology & therapeutics.

Effects of Ustekinumab Induction Therapy on Endoscopic and Histologic Healing in the UNIFI Phase 3 Study in Ulcerative Colitis

L. Peyrin-Biroulet, C. Marano, G. De Hertogh, 2019, Zeitschrift für Gastroenterologie.

OP35 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study

G. Rogler, L. Peyrin-Biroulet, B. Feagan, 2023, Journal of Crohn's and Colitis.

P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies

G. Rogler, L. Peyrin-Biroulet, M. Faes, 2022, Journal of Crohn's and Colitis.

OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study

J. Andrews, G. D'Haens, W. Reinisch, 2022, Journal of Crohn's and Colitis.

OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn’s Disease (CD) PTS: Results from IM-UNITI

S. Targan, P. Rutgeerts, S. Hanauer, 2016 .

DOP55 Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative Colitis

L. Peyrin-Biroulet, C. Marano, B. Feagan, 2022, Journal of Crohn's and Colitis.

P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy

G. D'Haens, L. Peyrin-Biroulet, S. Danese, 2023, Journal of Crohn's and Colitis.

DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results

D. McGovern, C. Siegel, R. Longman, 2023, Journal of Crohn's and Colitis.

OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results

L. Peyrin-Biroulet, S. Danese, J. Kierkuś, 2023, Journal of Crohn's and Colitis.

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.

G. Greenberg, B. Feagan, L. Nilsson, 1996, Gastroenterology.

Letter: limitations of studies to evaluate the significance of anti‐tumour necrosis factor serum levels in Crohn's disease – authors' reply

B. Feagan, B. Levesque, 2014, Alimentary pharmacology & therapeutics.

University of Birmingham Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy

C. Gasink, D. Jacobstein, B. Feagan, 2018 .

CDP 571 , a humanised monoclonal antibody to tumour necrosis factor a , for moderate to severe Crohn ’ s disease : a randomised , double blind , placebo controlled trial

G. Radford-Smith, R. Enns, B. Feagan, 2004 .

OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies

M. Ferrante, J. Lindsay, S. Schreiber, 2023, Journal of Crohn's and Colitis.

P436 Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial

C. J. van der Woude, S. Schreiber, W. Langholff, 2023, Journal of Crohn's and Colitis.